Chargement en cours...

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy. First‐ and second‐generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Chu, Chia‐Yu, Choi, Jennifer, Eaby‐Sandy, Beth, Langer, Corey J., Lacouture, Mario E.
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156184/
https://ncbi.nlm.nih.gov/pubmed/29650685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0582
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!